The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Mydrial     1-phenylpropan-2-amine

Synonyms: Adderall, Allodene, Thyramine, Amfetamine, AMPHETAMINE, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Mydrial


Psychiatry related information on Mydrial


High impact information on Mydrial

  • Lesions of the striato-nigral pathways (that is, crus cerebri or vicinity of the tail of the caudate nucleus) markedly attenuate depressant effects of intravenous d-amphetamine on central dopaminergic cell activity [12].
  • Dextroamphetamine for epilepsy [13].
  • Using event-related functional magnetic resonance imaging (fMRI), we conducted a within-subject, double-blind, placebo (PLAC)-controlled study of the effects of oral dextroamphetamine (AMPH, 0.25 mg/kg) treatment on brain activity and affect during incentive processing [14].
  • RESULTS: Subjects with MDD had a hypersensitive response to the rewarding effects of dextroamphetamine (2-fold increase; t(21) = 2.74, P = .01), with altered brain activation in the ventrolateral prefrontal cortex and the orbitofrontal cortex and the caudate and putamen (F(1,44) = 11.93, P = .001) [15].
  • BACKGROUND: The state of the brain reward system in major depressive disorder was assessed with dextroamphetamine, which probes the release of dopamine within the mesocorticolimbic system, a major component of the brain reward system, and produces measurable behavioral changes, including rewarding effects (eg, euphoria) [16].

Chemical compound and disease context of Mydrial


Biological context of Mydrial


Anatomical context of Mydrial


Associations of Mydrial with other chemical compounds


Gene context of Mydrial


Analytical, diagnostic and therapeutic context of Mydrial


  1. Dextroamphetamine with morphine for the treatment of postoperative pain. Forrest, W.H., Brown, B.W., Brown, C.R., Defalque, R., Gold, M., Gordon, H.E., James, K.E., Katz, J., Mahler, D.L., Schroff, P., Teutsch, G. N. Engl. J. Med. (1977) [Pubmed]
  2. Dextroamphetamine: cognitive and behavioral effects in normal prepubertal boys. Rapoport, J.L., Buchsbaum, M.S., Zahn, T.P., Weingartner, H., Ludlow, C., Mikkelsen, E.J. Science (1978) [Pubmed]
  3. Double-blind evaluation of reinforcing and anorectic actions of weight control medications. Interaction of pharmacological and behavioral treatments. Bigelow, G.E., Griffiths, R.R., Liebson, I., Kaliszak, J.E. Arch. Gen. Psychiatry (1980) [Pubmed]
  4. Implication of Bcl-2 family genes in basal and D-amphetamine-induced apoptosis in preneoplastic and neoplastic rat liver lesions. De Miglio, M.R., Muroni, M.R., Simile, M.M., Calvisi, D.F., Tolu, P., Deiana, L., Carru, A., Bonelli, G., Feo, F., Pascale, R.M. Hepatology (2000) [Pubmed]
  5. Effects of dopamine agonists in tardive dyskinesia. Smith, R.C., Tamminga, C.A., Haraszti, J., Pandey, G.N., Davis, J.M. The American journal of psychiatry. (1977) [Pubmed]
  6. Behavioral characterization of d- and l-amphetamine: neurochemical implications. Segal, D.S. Science (1975) [Pubmed]
  7. Levoamphetamine vs dextroamphetamine in minimal brain dysfunction. Replication, time response, and differential effect by diagnostic group and family rating. Arnold, L.E., Huestis, R.D., Smeltzer, D.J., Scheib, J., Wemmer, D., Colner, G. Arch. Gen. Psychiatry (1976) [Pubmed]
  8. Growth hormone response to dextroamphetamine in depressed patients and normal subjects. Halbreich, U., Sachar, E.J., Asnis, G.M., Quitkin, F., Nathan, R.S., Halpern, F.S., Klein, D.F. Arch. Gen. Psychiatry (1982) [Pubmed]
  9. Dexamphetamine for obsessive-compulsive disorder. Woolley, J.B., Heyman, I. The American journal of psychiatry. (2003) [Pubmed]
  10. Comments on "Amphetamine models of paranoid schizophrenia": a precautionary note. Rebec, G.V., Bashore, T.R. Psychological bulletin. (1982) [Pubmed]
  11. Individual differences in amphetamine self-administration: the role of the central nucleus of the amygdala. Cain, M.E., Denehy, E.D., Bardo, M.T. Neuropsychopharmacology (2008) [Pubmed]
  12. d-Amphetamine-induced inhibition of central dopaminergic neurons: mediation by a striato-nigral feedback pathway. Bunney, B.S., Achajanian, G.K. Science (1976) [Pubmed]
  13. Dextroamphetamine for epilepsy. Livingston, S., Pauli, L.L. JAMA (1975) [Pubmed]
  14. Amphetamine modulates human incentive processing. Knutson, B., Bjork, J.M., Fong, G.W., Hommer, D., Mattay, V.S., Weinberger, D.R. Neuron (2004) [Pubmed]
  15. Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe. Tremblay, L.K., Naranjo, C.A., Graham, S.J., Herrmann, N., Mayberg, H.S., Hevenor, S., Busto, U.E. Arch. Gen. Psychiatry (2005) [Pubmed]
  16. Probing brain reward system function in major depressive disorder: altered response to dextroamphetamine. Tremblay, L.K., Naranjo, C.A., Cardenas, L., Herrmann, N., Busto, U.E. Arch. Gen. Psychiatry (2002) [Pubmed]
  17. Fenfluramine and dextroamphetamine treatment of childhood hyperactivity. Clinical and biochemical findings. Donnelly, M., Rapoport, J.L., Potter, W.Z., Oliver, J., Keysor, C.S., Murphy, D.L. Arch. Gen. Psychiatry (1989) [Pubmed]
  18. Methylphenidate vs dextroamphetamine vs caffeine in minimal brain dysfunction: controlled comparison by placebo washout design with Bayes' analysis. Arnold, L.E., Christopher, J., Huestis, R., Smeltzer, D.J. Arch. Gen. Psychiatry (1978) [Pubmed]
  19. Paradoxical cortisol responses to dextroamphetamine in endogenous depression. Sachar, E.J., Halbreich, U., Asnis, G.M., Nathan, R.S., Halpern, F.S., Ostrow, L. Arch. Gen. Psychiatry (1981) [Pubmed]
  20. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Spencer, T., Biederman, J., Wilens, T., Faraone, S., Prince, J., Gerard, K., Doyle, R., Parekh, A., Kagan, J., Bearman, S.K. Arch. Gen. Psychiatry (2001) [Pubmed]
  21. Caffeine versus methylphenidate and d-amphetamine in minimal brain dysfunction: a double-blind comparison. Huestis, R.D., Arnold, L.E., Smeltzer, D.J. The American journal of psychiatry. (1975) [Pubmed]
  22. Lack of behavioral supersensitivity to d-amphetamine after pimozide withdrawal. A trial with schizophrenic patients. van Kammen, D.P., Docherty, J.P., Marder, S.R., Schulz, S.C., Bunney, W.E. Arch. Gen. Psychiatry (1980) [Pubmed]
  23. Cerebral glucose metabolism in adults with attention deficit hyperactivity disorder after chronic stimulant treatment. Matochik, J.A., Liebenauer, L.L., King, A.C., Szymanski, H.V., Cohen, R.M., Zametkin, A.J. The American journal of psychiatry. (1994) [Pubmed]
  24. Peptides and thermoregulation. Yehuda, S., Kastin, A.J. Neuroscience and biobehavioral reviews. (1980) [Pubmed]
  25. Early pharmacokinetics and clinical effects of oral D-amphetamine in normal subjects. Angrist, B., Corwin, J., Bartlik, B., Cooper, T. Biol. Psychiatry (1987) [Pubmed]
  26. Comparative symptomatological and evoked potential studies with d-amphetamine, thioridazine, and placebo in hyperkinetic children. Saletu, B., Saletu, M., Simeon, J., Viamontes, G., Itil, T.M. Biol. Psychiatry (1975) [Pubmed]
  27. Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Valjent, E., Pascoli, V., Svenningsson, P., Paul, S., Enslen, H., Corvol, J.C., Stipanovich, A., Caboche, J., Lombroso, P.J., Nairn, A.C., Greengard, P., Hervé, D., Girault, J.A. Proc. Natl. Acad. Sci. U.S.A. (2005) [Pubmed]
  28. Amygdala modulation of hippocampal-dependent and caudate nucleus-dependent memory processes. Packard, M.G., Cahill, L., McGaugh, J.L. Proc. Natl. Acad. Sci. U.S.A. (1994) [Pubmed]
  29. D-amphetamine disaggregates brain polysomes via a dopaminergic mechanism. Moskowitz, M.A., Weiss, B.F., Lytle, L.D., Munro, H.N., Wurtman, J. Proc. Natl. Acad. Sci. U.S.A. (1975) [Pubmed]
  30. Reciprocal changes in the firing rate of neostriatal and dorsal raphe neurons following local infusions or systemic injections of D-amphetamine: evidence for neostriatal heterogeneity. Rebec, G.V., Curtis, S.D. J. Neurosci. (1983) [Pubmed]
  31. Substantia nigra D1 receptors and stimulation of striatal cholinergic interneurons by dopamine: a proposed circuit mechanism. Abercrombie, E.D., DeBoer, P. J. Neurosci. (1997) [Pubmed]
  32. Alleviation of x-irradiation-based deficit in memory-based learning by D-amphetamine: suggestions for attention deficit-hyperactivity disorder. Highfield, D.A., Hu, D., Amsel, A. Proc. Natl. Acad. Sci. U.S.A. (1998) [Pubmed]
  33. Behavioral sensitization to amphetamine results from an uncoupling between noradrenergic and serotonergic neurons. Salomon, L., Lanteri, C., Glowinski, J., Tassin, J.P. Proc. Natl. Acad. Sci. U.S.A. (2006) [Pubmed]
  34. Importance of the noradrenaline-dopamine coupling in the locomotor activating effects of D-amphetamine. Darracq, L., Blanc, G., Glowinski, J., Tassin, J.P. J. Neurosci. (1998) [Pubmed]
  35. The SNAP25 gene as a susceptibility gene contributing to attention-deficit hyperactivity disorder. Feng, Y., Crosbie, J., Wigg, K., Pathare, T., Ickowicz, A., Schachar, R., Tannock, R., Roberts, W., Malone, M., Swanson, J., Kennedy, J.L., Barr, C.L. Mol. Psychiatry (2005) [Pubmed]
  36. The neuroendocrine and behavioral response to dextroamphetamine in normal individuals. Dommisse, C.S., Schulz, S.C., Narasimhachari, N., Blackard, W.G., Hamer, R.M. Biol. Psychiatry (1984) [Pubmed]
  37. Coloboma mouse mutant as an animal model of hyperkinesis and attention deficit hyperactivity disorder. Wilson, M.C. Neuroscience and biobehavioral reviews. (2000) [Pubmed]
  38. Dextroamphetamine enhances "neural network-specific" physiological signals: a positron-emission tomography rCBF study. Mattay, V.S., Berman, K.F., Ostrem, J.L., Esposito, G., Van Horn, J.D., Bigelow, L.B., Weinberger, D.R. J. Neurosci. (1996) [Pubmed]
  39. Modulation of use-dependent plasticity by d-amphetamine. Bütefisch, C.M., Davis, B.C., Sawaki, L., Waldvogel, D., Classen, J., Kopylev, L., Cohen, L.G. Ann. Neurol. (2002) [Pubmed]
  40. Differential effects of microinjections of d-amphetamine into the nucleus accumbens or the caudate putamen on the rat's ability to ignore an irrelevant stimulus. Solomon, P.R., Staton, D.M. Biol. Psychiatry (1982) [Pubmed]
WikiGenes - Universities